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PREVENTION OF BLEEDING 
AFTER CARDIOPULMONARY 
BYPASS WITH HIGH-DOSE 
TRANEXAMIC ACID 
Double-blind, randomized 
clinical trial 
This prospective, double-blind, randomized trial assessed the effectiveness 
of high-dose tranexamic acid given in the preoperative p riod on blood loss 
in patients undergoing cardiopulmonary b pass. One hundred fifty patients 
scheduled to undergo cardiac operations with cardiopulmonary b pass 
were randomized into three groups of equal size. The first group received 10 
gm of tranexamic acid intravenously over 20 minutes before sternotomy 
and a placebo infusion over 5 hours. The second group received 10 gm of 
tranexamic acid over 20 minutes and then another 10 gm infused intrave- 
nously over 5 hours. The control group received a placebo bolus and a 
placebo infusion ver 5 hours (0.9% normal saline solution). The blood loss 
after the operation was measured at 6 hours and 24 hours. The homologous 
blood and blood products given during and up to 48 hours after operation 
were recorded. Eighteen percent of the control group patients hed more 
than 750 ml blood in 6 hours compared with only 2% in both tranexamic 
acid groups. Patients who shed more than 750 ml blood required 93% more 
red blood cell transfusions than patients without excessive bleeding. 
Tranexamic acid (10 gm) given intravenously in the period before cardio- 
pulmonary bypass reduced blood loss over 6 hours by 50% and over 24 
hours by 35%. Continued tranexamic acid infusion (10 gm over 5 hours) did 
not reduce bleeding further. There was no difference in the coagulation 
profile before operation between patients with and without excessive 
bleeding. However, coagulation tests done in the postoperative period 
indicated ongoing fibrinolysis and platelet dysfunction in patients with 
excessive bleeding. (J THORAC CARDXOVASC SURG 1995;110:835-42) 
Jacek M. Karski, MD, a Sally J. Teasdale, MD, a Peter Norman, MD, a 
Jo Carroll, RN, Karl VanKessel, BSc, Peter Wong, BSc, and 
M. F. X. Glynn, MD, bt Toronto, Ontario, Canada 
T wenty percent of patients will bleed excessively after cardiac operations done with the use of 
cardiopulmonary b pass (CPB). Five percent of all 
patients having a cardiac operation will require 
immediate reoperation to control this excessive 
bleeding. 1 In 50% of patients undergoing reopera- 
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tion a surgical cause of bleeding is found. All other 
patients with excessive bleeding will be found to 
have coagulopathy. Patients having coagulopathy in
the postoperative period will often require massive 
transfusions of blood and blood products. 
This postoperative coagulopathy results from an 
activation of fibrinolysis and platelet dysfunction 
commonly seen after CPB. 2-6 With respect to fibrin- 
olysis, its prevention by synthetic antifibrinolytic 
administration (E-aminocaproic acid or tranexamic 
acid [TA]) to patients undergoing CPB has not 
always reduced bleeding. 7 This is because the dos- 
age and the timing of the use of antifibrinolytic 
drugs in cardiac operations have never been ade- 
quately established. With respect to blood platelets, 
structural and functional defects of the platelet 
receptors have been identified, s-l° Recently, it has 
been demonstrated that preservation of the platelet 
receptors in patients given aprotinin (Trasylol), an 
enzymatic inhibitor f fibrinolysis, correlates to a 
reduction of postoperative bleeding, s 
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In this institution, two antifibrinolytic agents, TA 
and e-aminocaproic a id, are routinely used prophy- 
lactically to prevent post-CPB bleeding. TA and 
E-aminocaproic a id exert heir antifibrinolytic effect 
through the formation of a reversible complex with 
a modified plasminogen) 1' 12 TA also competitively 
inhibits the activation of enteropeptidase and non- 
competitively inhibits its proteolytic activity. In ad- 
dition, it has a weak effect on thrombin and an even 
weaker inhibitive effect on plasmin. 13-15 The elimi- 
nation half-life of TA has been reported to be 80 
minutes 1« and about 90% of the dose is recovered 
from the urine after 24 hours. 16 Direct comparison 
of potencies indicates that TA is 6 to 10 times more 
potent than e-aminocaproic acid and sustains a 
greater antifibrinolytic activity in rat tissue) 7
Clearly, therapy designed to preserve the struc- 
ture and function of the patient's own circulating 
platelets would be preferred over the transfusion of 
homologous platelets. This suggests that if therapy 
designed to prevent damage to platelets is to be 
successful, the therapy should be given before the 
platelets are injured by the trauma of CPB. 9' 16, 18-23 
A review of our retrospective data published 
elsewhere 23has led us to conclude that TA given 
intravenously in a dosage of 10 gm (but not 6 gm) 
during the 1 hour before sternotomy would com- 
pletely prevent excessive bleeding after CPB (>750 
ml in the first 6 hours after CPB). This therapy has 
also resulted in a reduction in the number of 
patients receiving blood products. The effectiveness 
of TA in a dosage of 10 gm or greater in the 
reduction of post-CPB bleeding has not been stud- 
ied in a prospective manner. 
This prospective study was therefore designed to 
examine two problems. First, we studied the effect of 
pretreatment with TA before cardiac surgery on 
postoperative blood loss and the effectiveness of TA 
to eliminate xcessive bleeding in patients. Second, 
we examined whether it is possible to predict from 
preoperative t sts of the coagulation systems which 
patients will have excessive bleeding after operation. 
To answer these questions, we examined blood loss 
in the post-CPB period after a bolus dose of TA 10 
gm or a placebo was administered before sternot- 
omy followed by either an infusion of TA 10 gm or 
a placebo infusion and performed coagulation tests 
in the preoperative and postoperative periods. 
Methods 
The study was a prospective, double-blind, randomized 
trial (randomization was done by Toronto General Hos- 
pital, Research Division, Pharmacy). Approval for the 
study was received from our institution's ethics review 
board and informed consent was obtained from all pa- 
tients. 
One hundred fifty patients cheduled to undergo car- 
diac operations with CPB were randomized into three 
groups of equal size. The first group, designated TA-10, 
received an infusion of 10 gm of TA intravenously over 20 
minutes after induction of anesthesia nd a placebo 
infusion over the subsequent 5 hours. The second group, 
TA-20, received 10 gm of TA over 20 minutes and then a 
further 10 gm infused intravenously over 5 hours. The 
third group, a control group, received a placebo bolus and 
a placebo infusion over 5 hours (0.9% normal saline 
solution). All patients were stratified to either a high- or 
low-risk category with respect to bleeding and patients in 
these cätegories were equally distributed among the three 
groups. Patients at high risk were defined as those patients 
who had undergone previous cardiac operations with 
CPB, patients undergoing operation on more than one 
heart valve, patients undergoing aortacoronary b pass and 
operation on a heart valve, and patients undergoing 
operation because of septic endocarditis. All patients 
received high-dose fentanyl anesthesia, 50 to 75 /xg/kg, 
pancuronium 0.15 mg/kg, and diazepam 0.1 to 0.2 mg/kg. 
Heparin (300 units/kg) was given intravenously to achieve 
an activated clotting time of more than 400 seconds before 
CPB. Additional heparin was added throughout CPB to 
maintain activated clotting time at more than 400 seconds. 
After CPB, the effect of heparin was neutralized by 
administration f protamine sulfate (1 mg/100 units hep- 
arin) to achieve an activated clotting time _+10% of 
baseline values. 
The cardiac pump was primed with 2 L Ringer's lactate, 
100 ml 25% albumin, 50 mEq sodium bicarbonate, and 
100 ml 20% mannitol. A membrane oxygenator (Maxima, 
Medtronic, Inc., Minneapolis, Minn.) was used for all 
patients. 
The blood from the CPB circuit was salvaged and 
transfused to the patient at the end of the operation. The 
volume and hematocrit concentration of the blood that 
was suctioned from the operating site, excluding CPB, 
were measured and the number of grams of hemoglobin 
lost intraoperatively was calculated. 
After operation, blood loss from two mediastinal drains 
was collected in a sterile cardiotomy reservoir and auto- 
transfused to the patient when drainage xceeded 150 ml 
for the first 6 hours. Total blood loss was measured at 6 
and 24 hours. 
Homologous blood and blood products given during the 
operation and up to 48 hours after the operation were 
recorded. 
Itematologic and coagulation tests. Complete blood 
cell counts, including platelet counts, were done with a 
TOA electronic blood Cell counter (Baxter Industries, 
Toronto, Ontario, Canada) and checked for accuracy with 
a microscopic examination of a fixed, stained film. 
The bleeding times were determined with a bleeding 
time device (Template II, Organon-Teknika, Akzo, 
Pharma Group, Scarborough, Ontario, Canada). 
The prothrombin times and activated partial thrombo- 
plastin times were determined with standard commereial 
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reagents (Thromborel-S, Hoechst-Roussel, Montreal, 
Quebec, Canada; Platelin-LS, Organon-Teknika) in an 
automatic oagulation device (Automated Coagulation 
Laboratory, ACL, Coulter Electronics of Canada, Burl- 
ington, Ontario, Canada). 
The activißr of plasminogen and a2-antiplasmin were 
determined by means of a chromogenic substrate specific 
for each activiLty (Kabi-Pharmacia L boratories, Toronto, 
Ontario, Canada). 
The fibrinogen level was determined by the Clauss 
method. 
D-dimer values were determined by the latex aggluti- 
nation slide method with a commercial kit (Bio Pool, 
Burlington, Ontario, Canada). 
These tests were done before, during, and after the 
operation. 
Blood produet administration. Patients were given red 
blood cells (RBCs) if the hematocrit value was 19% or less 
during CPB or less than 20% on two consecutive mea- 
surements during intensive care unit (ICU) care after 
operation. Platelets, fresh frozen plasma, and cryoprecip- 
itate were given at the discretion of a single hematologist 
who was blinded to the study. Platelets (5 units) were 
given to the patient if the platelet count was less than 50 × 
109 L -1.  Cryoprecipitate (4 units) or fresh frozen plasma 
(1 unit) were given to patients if the prothrombin time was 
greater than 1.5 times normal value. Protamine sulfate, 25 
to 50 mg diluted in 50 ml of normal saline solution and 
infused over 30 minutes, was given in the ICU if the 
activated clotting time exceeded the baseline value for 
that patient by more than 10%. 
Patients who shed more than 200 ml blood per hour in 
2 consecutive hours or 400 ml in 1 hour were treated with 
E-aminocaproiLc acid 15 to 30 mg over 24 hours. The choice 
of e-aminocaproic a id for use in treating bleeding after 
operation was dictated by logistics because itwas available 
in the ICU and was the previous tandard treatment for 
bleeding after operation. Some patients who had excessive 
bleeding received esmopressin 0.4 tzg/kg diluted in 50 ml 
of normal saline solution and infused intravenously over 
30 minutes. 
Statistics. Sample size calculation was done with an 
assumption of a mean value difference among the groups 
of 200 ml blocd loss with standard eviation of 200 ml and 
alpha of 0.05 and beta of 80%. 
Blood loss volumes (in milliliters) at 6 and 24 hours 
were logarithmically transformed. Mean values of the 
blood loss in the three groups were compared by one- and 
two-way analysis of variance. When p = 0.05, multiple 
post-hoc comparisons were done (Tukey tests). Confi- 
dence intervals at 95% (CI.95) were calculated on loga- 
rithmically transformed values. Mean values and confi- 
dence intervals were then antilogarithmically transformed 
to milliliters of blood. Blood and blood products trans- 
fused were analyzed as a proportion of patients receiving 
them per group. CI.95 values were calculated for each 
proportion, and X z tests were used to compare frequen- 
cies. Continuous measurements were compared with anal- 
ysis of variance for within- and between-group effects. 
Data are presented as mean plus or minus the standard 
error of the mean, percent value, or number count. 
Table I. Demographic data and surgical 
characteristics 
Group 
TA- I O TA-20 Control 
(N = 49) (N = 50) (N = 48) 
Age (yr) 59 _+ 3 63 _+ 1 58 + 2 
Weight (kg) 79 _+ 2 80 _+ 2 80 -+ 2 
Hb preoperative 142 _+ 2 144 + 2 149 _+ 2* 
(gm/L) 
Hb postoperative 103 _+ 2 103 + 2 112 _+ 3 
(gm~) 
Bypass time (min) 99 _+ 5 99 _+ 5 93 -+ 5 
Lowest temperature 30.6 _+ 0.4 30.0 _+ 0.3 31.0 _+ 0.4 
on bypass (° C) 
No. of valve operations 14 10 8 
No. of CABG operations 33 37 35 
No. of valve 2 3 5 
+ CABG operations 
No. of operations 29 30 35 
involving LIMA 
No. of patients 31 32 34 
receiving ASA 
No. of patients with high- 28 27 30 
risk conditions 
No. of reoperations 6 12 11 
High risk for increased bleeding is defined as patients undergoing reop- 
eration, valve operation and coronary bypass, multiple valve procedures, or 
operation for septic endocarditis. Data are given as mean plus or minus 
standard error of the mean or number count. No statistically significant 
differences per treatment group were present, except preoperative hemo- 
globin level. Hb, Hemoglobin; CABG, coronary artery bypass grafting; 
LIMA, left internal mammary artery; ASA, acetylsalicylic a id. 
*p = o.os. 
Statistical analysis was done with the SYSTAT program, 
version 5.0 (Systat Inc., Evanston, Ill.). 
Three patients who underwent reoperation to control 
surgical bleeding were excluded from the statistical anal- 
ysis. 
Results 
Demographic  data and surgical characteristics are 
presented in Table I. Hemoglob in  concentrat ion 
before the operat ion was significantly higher in the 
control  group than in the t reatment  groups (p = 
0.05). 
The number  of pat ients who had excessive bleed- 
ing in the postoperat ive per iod is presented in Table 
II. A total of 11 patients had excessive bleeding 
during the early postoperat ive per iod (>750 ml in 
the first 6 postoperat ive hours). Nine patients (18%) 
in the control  group had excessive bleeding; how- 
ever, only one pat ient in the TA-10 group and one in 
the TA-20 group (2%, p = 0.001) had excessive 
bleeding. 
The patients who had excessive bleeding lost 
184% more blood during the initial 6 hours (p = 
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Table II. Excessive postoperative bleeding 
6 hr blood loss 6 hr blood loss 
Group >750 ml <750 ml 
TA-10 1 48 
TA-20 1 49 
Control 9* 39 
*p : o.ool. 
0.0001) and 77% more blood during the initial 24 
hours after operation than the remainder of the 
patients. Those patients who had excessive bleeding 
required an increased volume of autotransfusion 
(250%,p = 0.0001) and RBC transfusion (93%,p = 
NS*) than patients who did not have excessive 
bleeding (Fig. 1). Eight patients who had excessive 
bleeding received e-aminocaproic a id (10 to 40 gm) 
after operation. Only four patients in the group 
without excessive bleeding received e-aminocaproic 
acid (10 to 30 gm). There was no signifieant differ- 
ence in demographics between those patients who 
had excessive bleeding and those who did not. 
Amounts of blood loss in the TA-10, TA-20, and 
control groups during the first 24 hours after oper- 
ation are presented inFig. 2. During the first 6 hours 
after operation, there was a significant reduction in 
blood loss in both treatment groups (TA-10 group 
had a 50% reduction and TA-20 group had a 53% 
reduction) compared with blood loss in the control 
group (p = 0.0001). There was no significant differ- 
ence with respect o blood loss between the treat- 
ment groups, TA-10 and TA-20, during the first 6 
hours. 
Amounts of blood loss from 6 to 24 hours are 
presented in Fig. 2. During this 18-hour period, only 
the TA-20 group had significantly less bleeding than 
the control group (p = 0.03) with a 21% decrease in 
the blood loss. The TA-10 group had only an 18% 
decrease in blood loss compared with that in the 
control group, which is not statistically significant. 
Overall, during the first 24 hours after operation, 
there was a significant reduction in postoperative 
blood loss in both treatment groups (TA-10 group 
had a 35% and TA-20 group had a 37% reduction in 
blood loss) compared with that in the control group 
(p = 0.0001). There was no significant difference 
with respect o blood loss between the treatment 
groups over 24 hours. 
Intraoperative blood loss expressed as grams of 
hemoglobin did not differ between treatment and 
nontreatment groups; however, patients at high risk 
*NS = Not significant. 
for bleeding lost signifieantly more hemoglobin in- 
traoperatively (52 _ 35 gin) than patients at low risk 
(34 + 22 gm) (p = 0.001). 
There was no significant difference in transfusions 
of RBCs, platelets, cryoprecipitate, and fresh frozen 
plasma between treatment and control groups. 
Forty percent of patients received RBCs (mean 2 
units per patient receiving transfusion), only three 
patients received cryoprecipitate, and three patients 
received platelet eoncentrate. The strongest predic- 
tor of the need for RBC transfusion was the preop- 
erative hemoglobin level (p = 0.007 by univariate 
analysis). 
Autotransfusion was undertaken if the patient 
had greater than 150 ml blood loss in the first 6 
hours. Significantly fewer patients in the two treat- 
ment groups, TA-10 (27%, CI.95 39 to 15) and 
TA-20 (44%, CI.95 58 to 30), received an autotrans- 
fusion in comparison with the respective number in 
the control group (83%, CI.95 94 to 69, p = 0.001). 
Likewise, the volume of blood autotransfused was 
less in the treatment groups (TA-10, 44%; TA-20, 
52%) than in the control group. 
Results of coagulatiou tests. Results of the coag- 
ulation tests before and after operation did not 
differ among the three groups. To assess the differ- 
ences in coagulation systems between patients with 
and without excessive bleeding we analyzed the data 
of the 9 patients from the control group who had 
excessive bleeding and compared these results with 
those of 20 patients randomly selected from the 
control group who did not have excessive bleeding. 
Results of this comparison are presented in Tables 
III and IV. Results of coagulation tests done before 
operation did not differ among these two groups. 
However, results of the coagulation tests were dif- 
ferent between the two groups when done during 
and immediately after operation. Fibrinogen level 
was significantly lower after CPB in patients who 
had excessive bleeding. Plasminogen activity and 
a2-antiplasmin levels were significantly lower on 
arrival in the ICU in patients who had excessive 
bleeding. The plasminogen activity was still signifi- 
cantly lower 24 hours after CPB in patients with 
excessive bleeding. These patients with excessive 
bleeding had significantly prolonged bleeding times, 
prothrombin times, and activated partial thrombo- 
plastin times in the immediate postoperative p riod. 
Complieations. No patient had a perioperative 
myocardial infarction as indicated by electrocardio- 
graphic changes and plasma concentrations of car- 
diac enzymes. A total of three patients had a stroke 
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Fig. 1. Blood loss, autotransfusion, and RBC transfusion compared between patients with and without 
excessive bleeding. Patients with excessive bleeding lost significantly more blood and received significantly 
more autotransfusion a d RBC transfusion than patients without excessive bleeding. Bleeder, Patients with 
more than 750 ml blood loss in first 6 postoperative hours; non bleeder, patients with less than 750 ml blood 
loss in first 6 postoperative hours (20 patients randomly selected from control). 
1Patients who had excessive bleeding lost 184% more blo0d during initial 6 hours (p = 0.0001). 
2patients who had excessive bleeding required increased volume of autotransfusion (250%, p = 0.0001). 
3patients who had excessive bleeding received increased volume of RBC transfusion (93%, p = NS). 
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Fig. 2. Blood loss during periods from 0 to 6 hours, 6 to 24 hours, and 0 to 24 hours after operation. 
]Blood loss from 0 to 6 hours is reduced by 50% in TA-10 group and 53% in TA-20 group compared with 
that in control group (p = 0.0001). There was no difference in blood loss between TA-10 and TA-20 groups. 
2Blood loss from 6 to 24 hours was reduced by 21% in TA-20 group compared with that in control group 
(p = 0.03). Blood loss in TA-10 group was not statistically significant when compared with that in control group. 
3Total blood loss during first 24 hours after operation was reduced by 35% in TA-10 group and 37% in 
TA-20 group compared with that in control group (p = 0.0001). There was no difference in blood loss 
between TA-10 and TA-20 groups. 
after operation. Two of these patients were in the 
TA-10 group, one in the TA-20 group, and none in 
the control group (p = NS). All three patients had 
advanced widespread peripheral vascular disease 
and two had had previous strokes. 
Discuss ion  
The most important conclusion of this study is 
that a single 10 gm dose of TA  given intravenously 
before sternotomy reduces the percentage of pa- 
tients who have excessive bleeding (more than 750 
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Table III. Hemotologic and coagulation findings 
Group PT (sec) aPTT (sec) Bleeding time (min) 
Normal fange 9.8-12 25-38 <6 
Before operation 
Patients with excessive bleeding 11.3 -+ 0.3 31.7 --- 2.4 4.7 --_ 0.5 
Patients without excessive bleeding 11.2 + 0.5 28.3 _+ 1.1 4.1 _+ 0.4 
p Value NS NS NS 
After operation 
Patients with excessive bleeding 17.0 -+ 0.5 39.7 -+ 2.4 11.0 _+ 1.2 
Patients without excessive bleeding 15.0 _+ 0.4 32.8 _+ 1.0 6.5 + 1.2 
p Value 0.006 0.004 0.03 
4 hr post-CPB 
Patients with excessive bleeding 13.7 -4- 0.7 30.3 - 3.4 NA 
Pafients without excessive bleeding 13.7 + 0.6 28.9 -+ 1.5 NA 
p Value NS NS NA 
12 hr post-CPB 
Patients with excessive bleeding 14.7 _+ 0.4 36.8 -+ 2.9 7.6 + 1.2 
Patients without excessive bleeding 13.6 ~ 0.3 31.7 --- 1.3 4.7 +- 0.4 
p Value 0.03 NS 0.01 
Comparison of the coagulation profile between 9patients with excessive bleeding from the control group and 20 patients without excessive bleeding from the 
control group. Patients with excessive bleeding shed more than 750 ml blood in the first 6 postoperative hours; patients without excessive bleeding shed less 
than 750 ml blood in the first 6 postoperative hours. Data are given as mean plus nr minus tandard error of the mean. PT, Prothrombin time; aPT'I;, activated 
partial thromboplastin time; NS, not significant; NA, not available. 
Table IV. Hemotologic and coagulation findings 
Plasminogen Fibrinogen a2-Antiplasmin 
activity level D-dimers activity Platelets Hematocrit 
Group (units/ml) (gm/L) (ng/ml) (units/ml) (billion~L) (L/L) 
Normal range 0.8-1.2 1.5-3.5 <500 0.8-1.2 150-400 0.40-0.54 
Before operation 
Patients with excessive bleeding 0.95 _+ 0.02 3.3 _+ 0.2 394 _+ 52 1.09 --- 0.05 249 _+ 10 0.43 _+ 0.03 
Patients without excessive bleeding 0.95 --- 0.04 3.4 _+ 0.2 373 -4- 43 1.01 --- 0.03 224 -+ 16 0.43 _+ 0.01 
p Value NS NS NS NS NS NS 
After sternotomy 
Patients with excessive bleeding 0.89 -4- 0.05 2.8 - 0.2 350 - 48 0.94 - 0.05 209 +_ 7 0.38 _+ 0.01 
Patients without excessive bleeding 0.87 -+ 0.03 3.5 --_ 0.2 367 -+ 44 0.93 -+ 0.03 179 +- 9 0.37 --- 0.01 
p Value NS 0.06 NS NS 0.05 NS 
End of CPB 
Patients with excessive bleeding 0.48 --- 0.04 1.4 --- 0.1 408 --- 38 NA 158 _+ 10 0.23 _+ 0.01 
Patients without excessive bleeding 0.53 --- 0.02 2.0 --- 0.2 366 -+ 34 NA 148 -+ 11 0.25 +- 0.01 
p Value NS 0.02 NS NA NS 0.01 
ICU 
Patients with excessive bleeding 0.43 _+ 0.05 1.3 +- 0.2 746 + 186 0.52 + 0.03 107 - 7 0.23 +-- 0.01 
Patients without excessive bleeding 0.62 - 0.03 2.3 --- 0.2 839 +-_ 176 0.69 _+ 0.04 130 _+ 10 0.27 -2-- 0.01 
p Value 0.003 0.008 NS 0.007 NS 0.02 
24 hr post-CPB 
Patients with excessive bleeding 0.41 + 0.04 2.9 -+ 0.4 513 + 82 NA 114 + 8 0.25 +- 0.01 
Patients without excessive bleeding 0.69 -- 0.04 3.8 --- 0.3 630 -+ 194 NA 130 -+ 11 0.27 -- 0.01 
p Value 0.0001 NS NS NA NS NS 
Comparison of the coagulation profile between ine patients with excessive bleeding from the control group and 20 patients without excessive bleeding from 
the control group. Patients with excessive bleedingshed more than 750 ml blood in the first 6 postoperative hours; patients without excessive bleeding shed 
less than 750 ml blood in the first 6 postoperative hours. Data are given as mean plus or minus standard error of the mean. NS, Not significant; NA, not 
available. 
ml in 6 hours) after CPB ffom 18% to 2%. In 
addition, 10 gm of TA reduces blood loss in the 
postoperative p riod by 50% during the first 6 hours 
and by 35% during the first 24 hours after operation 
in comparison with the use of placebo. An addi- 
tional 10 gm of TA (20 gm in total) in a subsequent 
5-hour infusion did not improve blood preservation 
after operation. These findings confirm out previous 
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results and indicate that pretreatment with the 
antifibrinolytic agent TA (10 gm) before CPB pre- 
vents excessive postoperative blood loss and reduces 
the need for blood transfusion. The reduced need 
for RBC transfusion (93%) was evident when pa- 
tients with and without excessive bleeding were 
compared. The difference in RBC transfusion be- 
tween these groups was not statistically significant 
probably because of the small number of patients 
being compared (9 with and 20 without bleeding). 
Overall, there was no difference in the RBC trans- 
fusion requirement between the treatment and con- 
trol groups. The control group had a significantly 
higher preoperative hemoglobin level, and, in addi- 
tion, patients from the control group who had 
excessive bleeding received autotransfusion and 
were treated with antifibrinolytic drugs for ethical 
reasons. Autotransfusion and drug treatment re- 
duced blood loss and the need for RBC transfusion 
within the control group. 
Results from coagulation tests done during this 
study indicate that there are no differences in coag- 
ulation parameters before operation between pa- 
tients with and without excessive bleeding. Thus it is 
impossible to predict with the use of standard 
eoagulation tests who will have excessive bleeding 
after heart operations done with CPB. Results from 
coagulation tests done after operation clearly indi- 
cate that patients with excessive bleeding had ongo- 
ing coagulopathy (increased fibrinolysis and platelet 
dysfunction) on arrival at the ICU. These changes in 
the coagulation system, which started immediately 
after sternotomy, persisted for up to 24 hours after 
operation. Similar changes in coagulation parame- 
ters were observed in two patients from the TA 
groups with excessive bleeding. The most probable 
causes of excessive bleeding were increased fibrin- 
olysis (decreased plasminogen activity and de- 
creased a2-antiplasmin activity) and abnormal plate- 
let function (prolonged bleeding time) seen after the 
operation. We assume that by giving the antifibrino- 
lytie agent TA before operation we were able to 
prevent fibrinolysis and protect platelets, which, as 
indicated by Huang and co-workers 8 and Soslau, 
Horrow, and Brodsky, 9eliminated excessive bleed- 
ing in the postoperative p riod. 
The exact mechanism of induction of fibrinolysis 
by CPB is not clear. It is thought that fibrinolysis 
during cardiac operations with CPB is likely elicited 
physiologically by thrombin generation and fibrin 
production. Plasmin generated uring activation of 
fibrinotysis has a damaging effect on platelet func- 
tion. It is postulated by Lu and associates 24that a 
low concentration of plasmin (0.1 to 1.0 CU*/ml) 
inhibits platelet activation by thrombin or collagen 
and that a high concentration of plasmin (>1.5 
CU/ml) activates platelets. • 
With respect to the type of platelet damage 
induced by fibrinolysis and plasmin formation, two 
recent papers suggested that platelet receptors are 
differentially redistributed by the effect of plas- 
rain.Z5, 26 Plasmin treatment of the platelets at nor- 
mothermia resulted in the disappearance of platelet 
glycoprotein Ib from the cell surface and its subse- 
quent redistribution i to the channels and vesicles 
of the surface-connected canalicular system with 
significantly modified glycoprotein IIb/IIIa remain- 
ing on the plasma membrane. Disappearance of the 
glycoprotein Ib from the platelet surface prevents 
effective binding of the platelets to von Willebrand's 
factor and inhibits initiation of clotting. These re- 
sults were not supported by the findings of Kestin 
and associates 1° in which the authors concluded that 
CPB results in markedly deficient platelet reactivity 
in response to the in vivo wound in whieh platelet 
surface glycoproteins Ib and IIb/IIIa are preserved. 
They concluded that platelet dysfunction after CPB 
is not a defect intrinsic to the platelets, but rather an 
extrinsic defect such as in vivo lack of availability of 
platelet agonists. Although there is not a consensus 
as to the nature of damage inflicted on platelets by 
CPB the end point remains the same: excessive 
blood loss after operation. 
We have seen excessive bleeding in 18% of pa- 
tients undergoing CPB who have not received TA 
before operation, and it will remain unknown for some 
time why only these patients had excessive bleeding. 
Future research should be directed toward the preop- 
erative diagnosis of the risk for excessive postoperative 
blood loss. Subsequently, only those patients who are 
at risk should be pretreated with äntifibrinolytic drugs 
before CPB, which will reduce expense and limit the 
exposure to antifibrinolytic agents. Until that time, the 
best way to protect patients from excessive blood loss 
after cardiac operation is to pretreat all patients with 
an antifibrinolytic agent before operation thereby pre- 
venting plasmin formation and subsequent damage to 
platelets. 
We express our appreciation for the contribution of the 
cardiac surgeons of The Toronto Hospital and Dr. Eric 
Yeo, staff hematologist, for his help in interpreting the 
hematologic and coagulation data. 
*CU = Caseinolyt ic  unit.  
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